A Administração de Alimentos e Medicamentos dos EUA (FDA) concedeu a designação de “Terapia Inovadora” ao cobimetinibe para o tratamento de pacientes com neoplasias histiocíticas (doença de Erdheim-Chester, síndrome de Rosai-Dorfman, histiocitose de Langerhans) que não apresentam a mutação BRAF V600. Isso...
A ECD Global Alliance concede uma bolsa de pesquisa sobre a doença de Erdheim-Chester ao MSKCC com o objetivo de identificar a população de células responsáveis pelo início da doença na ECD e comparar as alterações genéticas.
The ECD Global Alliance welcomes Duke Cancer Institute in Durham, NC into the referral care center network that serves ECD patients worldwide. Richard F. Riedel, MD will be leading the institute’s team at the Emerging Referral Care Center.
The ECD Global Alliance announces the launch of the Registry for Patients with Erdheim-Chester Disease led by Memorial Sloan Kettering Cancer Center (MSK), in New York, NY. The next step in building the registry database includes recruiting patients with ECD to...
Medical residents and physicians at Houston Methodist Hospital in Houston, TX learned about Erdheim-Chester disease from ECD Care Center lead, Mark Heaney, MD, PhD from Columbia University Medical Center. Also in attendance was ECDGA President, Kathy Brewer.
